PA
CTKB icon

Perceptive Advisors’s Cytek Biosciences CTKB Stock Holding History

Perceptive Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,289,534
Closed -$11.9M – 99
2023
Q1 		$11.9M Hold
1,289,534
– – 0.35% 61
2022
Q4 		$13.2M Hold
1,289,534
– – 0.37% 54
2022
Q3 		$19M Buy
+1,289,534
New +$16.7M 0.55% 45

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Perceptive Advisors's CTKB Position: Q2 2023 in Review

Perceptive Advisors sold out of Cytek Biosciences (CTKB) in Q2 2023, closing a stake of 1,289,534 shares — an estimated $11.9M sold.

Perceptive Advisors first reported a position in CTKB in Q3 2022 and held it in 3 quarters. The position peaked at $19M in Q3 2022. 101 funds tracked by Wall St. Rank hold CTKB as of Q2 2023.

  • Perceptive Advisors reported no remaining Cytek Biosciences position as of Q2 2023 after selling out during the quarter.
  • Perceptive Advisors sold 1,289,534 Cytek Biosciences shares in Q2 2023, an estimated $11.9M.
  • Perceptive Advisors first reported a position in Cytek Biosciences in Q3 2022 and held it in 3 quarters.
  • Perceptive Advisors's Cytek Biosciences position peaked at $19M in Q3 2022.
  • 101 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2023.

Based on Perceptive Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.